Concern over new biosimilars law
AUSTRALIA’S world-first decision to allow pharmacists to substitute biologic drugs has sparked medical and consumer group concern about patient safety.
A bill, passed as part of the PBS reform package, allows biosimilar substitution at a pharmacy level and is expected to save the PBS $880 million over five years.
While the savings may benefit patients, it is “too much of a worry” to leave such a decision in the hands of pharmacists, says Dr Evan Ackermann, chair of the RACGP’s National Standing Committee on Quality Care. “It’s a clinical